Pharmafile Logo
Pharmafocus logo
Advanced Search

Dendreon

Showing 15 posts of 16 posts found.

valeant_web

Valeant to sell cancer business to Sanpower for $820m

January 10, 2017
Manufacturing and Production, Sales and Marketing Dendreon, Sanpower, Valeant

Valeant Pharmaceuticals has announced it is to sell its cancer business Dendreon to Chinese firm Sanpower in a deal worth …

News
dendreon image

Another NICE no for Dendreon cancer drug

January 13, 2015
Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T

Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …

News
Dendreon image

Dendreon files for bankruptcy

November 12, 2014
Research and Development, Sales and Marketing Dendreon, Provenge, awick, delaware, johnson, nj

Dendreon Corporation, the troubled manufacturer of high-cost cancer vaccine Provenge, has filed for bankruptcy as a prelude to restructuring its …

News

NICE not recommending Dendreon cancer vaccine

October 16, 2014
Sales and Marketing Dendreon, NHS, NICE, Provenge, sipuleucel-T, therapeutic cancer vaccine

NICE has issued preliminary draft guidance not recommending Dendreon’s therapeutic cancer vaccine Provenge for prostate cancer in people whose disease …

News
John Johnson image

Dendreon chief resigns from struggling firm

June 10, 2014
Medical Communications, Sales and Marketing Cancer, Dendreon, John Johnson, Provenge, Vaccine, Watson, prostate

Chief executive of Dendreon John Johnson is to step down in the summer amid falling sales of the company’s key …

News
dendreon image

Dendreon slashes more jobs

November 13, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Dendreon, Provenge, cuts

Another 150 jobs are to go at Dendreon Corporation as the company seeks to cut $125 million per year in …

News

Dendreon wins Provenge authorisation

September 19, 2013
Research and Development, Sales and Marketing Dendreon, Provenge, prostate cancer

News

Dendreon slashes staff and closes facility

July 31, 2012
Manufacturing and Production, Sales and Marketing Dendreon, M&P, Provenge, prostate cancer

Cancer vaccine specialist Dendreon has said it will slash 600 jobs and close one of its three manufacturing facilities in …

News
screen_shot_2012-07-05_at_11

New chairman of the board for Dendreon

July 5, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dendreon, Provenge, johnson, prostate cancer

Dendreon has announced that its president and chief executive John Johnson has assumed the additional title of chairman of the …

Appointment

Slow Provenge growth prompts Dendreon staff cull

September 13, 2011
Business Services, Manufacturing and Production Dendreon, Provenge, job cuts, pharma manufacturing news

After months of building manufacturing capacity, US biotech Dendreon has decided to slash a quarter of its workforce – with …

News

Dendreon drops GSK as Provenge manufacturing partner

September 8, 2011
Manufacturing and Production Dendreon, GSK, Provenge, pharma manufacturing news

Dendreon has called a halt to its manufacturing and supply deal with GlaxoSmithKline for cancer vaccine Provenge, citing “delays and …

News

Dendreon wins green light for Provenge production

March 22, 2011
Manufacturing and Production Cancer, Dendreon, FDA, Provenge, pharma manufacturing, prostate cancer vaccine, sipuleucel-T

US oncology specialist Dendreon has been boosted by the approval of additional production capacity for its therapeutic prostate cancer vaccine …

News

Dendreon will outsource first Provenge production in EU

January 11, 2011
Manufacturing and Production Dendreon, Provenge, cancer vaccine, contract manufacturing, sipuleucel-T, vaccine manufacturing, vaccines

US oncology specialist Dendreon has decided to hire a contract manufacturer for its cell-based cancer therapy Provenge in Europe to …

News

Bavarian Nordic courting cancer vaccine backers

November 12, 2010
Research and Development, Sales and Marketing Bavarian Nordic, Dendreon, Prostvac, Provenge, TroVax, cancer vaccine, prostate cancer, prostate cancer vaccine, zibotentan

Danish biotech Bavarian Nordic is in ‘advanced discussions’ with a number of potential pharma partners for its phase II therapeutic …

News

Oxford BioMedica hopes vaccine first will raise interest

May 5, 2010
Sales and Marketing Dendreon, Oxford BioMedica, Provenge, TroVax

Oxford BioMedica is hoping that the approval of the world’s first immunotherapy cancer vaccine in the US will help it …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024